Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Safety and Efficacy of First-Line Nivolumab...
Conference

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC) Metastatic Non-Small Cell Lung Cancer

Authors

Antonia SJ; Gettinger S; Goldman J; Chow LQ; Juergens R; Borghaei H; Brahmer JR; Shen Y; Harbison C; Chen AC

Volume

90

Pagination

pp. s32-s33

Publisher

Elsevier

Publication Date

11 2014

DOI

10.1016/j.ijrobp.2014.08.207

Conference proceedings

International Journal of Radiation Oncology • Biology • Physics

Issue

5

ISSN

0360-3016